


Novel Highly Tumour-restricted Antigens and Antibodies for Cancer Therapy

Cumulus Oncology identifies and funds the progression of early-stage opportunities to develop novel differentiated anti-cancer therapies, with the aim of improving outcomes for cancer patients. They are interested in identifying and engaging with academics who have **highly tumour-restricted antigens** or **monoclonal or multivalent antibodies that target them** which have the potential for therapeutic activity in cancer.



Approaches of Interest:

- **Novel monoclonal antibodies, bi- and / or tri-specific antibodies that bind highly tumour-restricted antigens** which are either **expressed on the tumour or essential mediator cells** in the tumour microenvironment, including NK cells and cancer-associated fibroblasts
- Research opportunities where **novel highly tumour-restricted antigens have been identified** and for which a therapeutic antibody approach could be developed. **Embryonic cell targets** are the priority, but others will be considered if the target is sufficiently tumour-specific to minimise off-target toxicity
- All cancers are within scope, with **solid tumours being of highest interest**. Patient populations with the **worst survival outcomes will be prioritised**, particularly where there is the potential to treat more than one type of cancer
- Projects which have a **fully human or humanised antibody** will be prioritised

Out of Scope:

- Drug repurposing approaches, small molecule, small antibodies (Fabs, diabodies, nanobodies etc), antibody drug conjugates, immunotoxins, radioimmunotherapy, gene therapy and cell-based therapeutics

Developmental Stages of Interest:

- Basic research phase to prior IND-enabling preclinical studies are within scope. Projects with *in vivo* validation are of the highest interest, although opportunities with strong *in vitro*, *ex vivo* or target-binding data will be considered

Submission Information:

Submissions should contain 200-300 word briefs along with the following optional **submission form**, highlighting any relevant data and supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration:

Cumulus Oncology is open to a range of collaboration scenarios, determined on a case by case basis. Potential outcomes include investment and licensing (development of assets and potential spin-out companies), research collaborations (building longstanding relationships with academic teams), and involvement in the scientific review and further development of assets. The seasoned experts from Cumulus Oncology will support and drive development of the asset towards clinical studies.

Opportunities sought

- 💡 Technologies
- 🎓 Academics and expertise
- 🏆 Centres of excellence
- 🧪 Research projects
- 🏢 Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **2nd May 2023 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

